Avivagen Reports Final Poultry Trial Results

Avivagen Inc. (TSXV:VIV) announced the final results of its poultry trial, which tested OxC-beta™ Livestock for preventing morbidity resulting from bacteria, a global poultry production issue.

As quoted in the press release:

The pathogen, Clostridium perfringens, causes a condition called necrotic enteritis (“NE”) that consists of intestinal damage that reduces producer economics and can also cause sickness or death. NE is a frequent reason for prophylactic use of antibiotics in poultry feeds.

The trial was conducted in broiler chickens and first reconfirmed the optimal levels of OxC-beta in this subclinical NE challenge model. It then conducted two parallel replicates of a main trial that consisted of seven study arms: testing three commercially-relevant levels of OxC-beta and two commonly-used Antibiotic Growth Promoters (AGPs) against a negative control group (non-medicated infected) and a positive control group (non-medicated uninfected).

President and CEO of Avivagen, Cameron Groome, commented:

As with a prior Canadian NE challenge trial in broiler chickens, we believe these results demonstrate that OxC-beta™ Livestock is a valuable new tool for poultry producers. Regulators are increasing restrictions on the use of antibiotics for disease prevention, so there is a growing need for in-feed alternatives like OxC-beta.

We are now moving ahead with confirming these broiler chicken results in the commercial operations of major poultry producers. Additionally, it is our intention to evaluate the benefits of OxC-beta for layer hens – another important poultry market.

Click here to read the full Avivagen Inc. (TSXV:VIV) press release.